| scholarly article | Q13442814 |
| P2093 | author name string | Xiang Wang | |
| Carlos Fernandez-Patron | |||
| Zamaneh Kassiri | |||
| Tatsujiro Oka | |||
| Stephan Cooper | |||
| Jeffrey Odenbach | |||
| Fung Lan Chow | |||
| Gary Lopaschuk | |||
| P2860 | cites work | Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. | Q43134563 |
| Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy | Q43851616 | ||
| Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. | Q44108423 | ||
| Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats | Q44470607 | ||
| Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway | Q44680897 | ||
| Cross talk between angiotensin II and alpha 1 adrenergic receptors in rabbit aorta: role of endothelium | Q44838846 | ||
| Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. | Q46034394 | ||
| ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload | Q46043843 | ||
| Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach | Q46616535 | ||
| Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species | Q46902325 | ||
| Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis | Q48534691 | ||
| Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. | Q50667791 | ||
| A factor that initiates myocardial hypertrophy in hypertension | Q70166111 | ||
| Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction | Q73071887 | ||
| Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors | Q73120315 | ||
| Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor | Q73175870 | ||
| ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II | Q79903880 | ||
| Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases | Q28573756 | ||
| Human progelatinase A can be activated by matrilysin | Q28618916 | ||
| EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF | Q29619098 | ||
| Endothelial-to-mesenchymal transition contributes to cardiac fibrosis | Q29620566 | ||
| Molecular mechanisms of human hypertension | Q32138445 | ||
| MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice | Q33521236 | ||
| Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. | Q33994864 | ||
| CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling | Q35005223 | ||
| Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney | Q35215135 | ||
| Myocardial collagen matrix remodelling in arterial hypertension | Q35376096 | ||
| Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial | Q36644664 | ||
| ECM remodeling in hypertensive heart disease | Q36749281 | ||
| Mechanisms of cardiac fibrosis in hypertension | Q36873139 | ||
| p53 Mediates epidermal growth factor (EGF) induction of MMP-2 transcription and trophoblast invasion | Q38349423 | ||
| p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity | Q39752793 | ||
| The athlete's heart syndrome: a new perspective | Q39837204 | ||
| Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator | Q40526206 | ||
| Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction | Q41817544 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzymologic gene expression regulation | Q70688407 |
| P304 | page(s) | 123-130 | |
| P577 | publication date | 2010-11-15 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | MMP-2 Mediates Angiotensin II–Induced Hypertension Under the Transcriptional Control of MMP-7 and TACE | |
| P478 | volume | 57 |
| Q28072451 | A Disintegrin and Metalloprotease 17 in the Cardiovascular and Central Nervous Systems |
| Q64925064 | A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy. |
| Q35848839 | A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature |
| Q41963486 | ADAM17 mediates OSCC development in an orthotopic murine model. |
| Q38621957 | ADAMs family and relatives in cardiovascular physiology and pathology. |
| Q37955866 | An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q37859447 | Angiotensin II and the vascular phenotype in hypertension |
| Q37494963 | Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK |
| Q50080358 | Beyond the matrix: MMP2 as critical regulator of inflammation-mediated vascular dysfunction |
| Q50972674 | CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα12/13. |
| Q35152779 | Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. |
| Q37263881 | Development of nonfibrotic left ventricular hypertrophy in an ANG II-induced chronic ovine hypertension model |
| Q38095579 | Do intravenous and subcutaneous angiotensin II increase blood pressure by different mechanisms? |
| Q50019267 | Electrical and histological remodeling of the pulmonary vein in 2K1C hypertensive rats: Indication of initiation and maintenance of atrial fibrillation |
| Q51369845 | Elevated levels of MMP-9 in untreated patients with stage I essential hypertension. |
| Q37731726 | Endoplasmic reticulum stress contributes to aortic stiffening via proapoptotic and fibrotic signaling mechanisms |
| Q38061567 | Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease |
| Q42824278 | Insufficient glucose supply is linked to hypothermia upon cold exposure in high-fat diet-fed mice lacking PEMT. |
| Q92708892 | Leukocyte matrix metalloproteinase and tissue inhibitor gene expression patterns in children with primary hypertension |
| Q35588952 | Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton |
| Q36538088 | Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study |
| Q61654703 | Matrix Proteins and Proteinases Network in Human Cardiovascular Diseases Explored By Cytoscape |
| Q46289718 | Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury |
| Q42773403 | Matrix metalloproteinases activities in hypertension: emerging opportunities |
| Q37962503 | Matrix metalloproteinases and small artery remodeling |
| Q35175533 | Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis |
| Q36960275 | Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling |
| Q38224470 | Metalloproteinases in hypertension and cardiac disease: differential expression and mutual regulation |
| Q33807027 | Metalloproteinases: key and common mediators of multiple GPCRs and candidate therapeutic targets in models of hypertensive cardiac disease |
| Q58703037 | MiR-665 aggravates heart failure via suppressing CD34-mediated coronary microvessel angiogenesis |
| Q38268844 | Mitochondria: a pathogenic paradigm in hypertensive renal disease |
| Q33807091 | Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets? |
| Q45801913 | New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. |
| Q92850623 | Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies? |
| Q40845859 | Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. |
| Q53704529 | Platelet CD40 contributes to enhanced monocyte chemoattractant protein 1 levels in patients with resistant hypertension. |
| Q33773304 | Regulation and involvement of matrix metalloproteinases in vascular diseases |
| Q50501810 | Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy. |
| Q37944417 | The dynamic structure of arterioles |
| Q26749488 | Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications |
| Q36114331 | α-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. |
Search more.